BioNTech and Pfizer have announced that they are initiating a phase 1 study to evaluate a single dose mRNA-based combination vaccine candidate against influenza and COVID-19 – a novel combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results